Z Gastroenterol 2021; 59(08): e332
DOI: 10.1055/s-0041-1734242
POSTER
CED

Antibody response to bnt162b2 mRNA vaccine in patients with IBD or chronic liver disease

M Piribauer
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
P Bergmeister
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
C Frick
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
J Johannes
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
B Mutschlechner
2   Feldkirch Academic Teaching Hospital, Department of Internal Medicine I, Feldkirch, Austria
,
M Benda
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
C Grabher
3   Medical Central Laboratories, Feldkirch, Austria
,
P Fraunberger
3   Medical Central Laboratories, Feldkirch, Austria
,
H Ulmer
4   Innsbruck Medical University, Department of Medical Statistics, Informatics and Health Economics, Innsbruck, Austria
,
B Hartmann
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
P Peters
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
,
T Winder
1   Feldkirch Academic Teaching Hospital, Department of Internal Medicine II, Feldkirch, Austria
5   University of Zurich, Zürich, Switzerland.
› Author Affiliations
› Further Information
Also available at
 

Background Patients with inflammatory bowel disease (IBD) or chronic liver disease (CLD) on immunosuppressive therapy show poor response to different vaccinations, and were not included in registrational trials for BNT162b2. The aim of our study was to evaluate serologic antibody response and safety of BNT162b2 mRNA vaccine in patients with IBD or CLD on immunosuppressive therapy.

Methods By this retrospective data analysis, serological antibody response and adverse events were assessed in patients with IBD or CLD vaccinated with two 30µg doses of BNT162b2 administered 21 days apart. Serological antibody response was assessed by ELECSYS® Anti-SARS-CoV-2-S immunoassay before vaccination (T0), 21 days after first (T1), and 21 days after full immunization (T2). Standardized safety questionnaire was used for safety assessment.

Results A total of 84 patients were included in the data analysis, including 67 patients with IBD and 17 patients with CLD. After the 2nd vaccination, seroconversion of the SARS-CoV-2 antibodies to S/RBD was seen in all (100 %) included patients. Strikingly, we could show that patients with Crohn’s disease had lower antibody titer in comparison to the other subgroups (p = 0.02), furthermore higher mean antibody titers at T1/T2 were seen in patients seropositive at baseline (p < 0.001). Vaccinations were well tolerated overall, with a total of 6 events of grade 4 adverse reaction, but no grade 5 adverse reaction. Side effects after the 2nd vaccination were more frequent under ongoing therapy with TNF blockers (p = 0.026) and in patients under 50 years (p = 0.012).

Conclusion In patients with IBD and CLD serologic antibody response after BNT162b2-vaccination is comparable to the general population. The occurrence of side effects, is more common in patients on TNF blocker therapy and in younger patients, yet BNT162b2 is safe to use in this patient population under real world condition.



Publication History

Article published online:
01 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany